{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stratton MP"],"funding":["RFUMS","Batten Disease Support and Research Association","NINDS NIH HHS","NIH HHS"],"pagination":["gkaf1141"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12585909"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["53(20)"],"pubmed_abstract":["CLN3 Batten disease is a lethal pediatric neurodegenerative disease caused by mutations in the CLN3 gene. Typically, the disease manifests as vision loss in early childhood and progresses to neurological dysfunction and death in young adulthood. Most therapeutic developments have focused on treating the brain and may not protect against vision loss, which greatly affects quality of life. We have previously shown that a splice-switching antisense oligonucleotide (ASO) delivered to the central nervous system can reduce neurological disease burden in mouse models of CLN3 disease. Here, we apply a similar ASO approach for treating retinal dysfunction in a pig model of CLN3 Batten disease, which is more representative of human vision. A single intravitreal injection of ASO induces robust exon s"],"journal":["Nucleic acids research"],"pubmed_title":["Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease."],"pmcid":["PMC12585909"],"funding_grant_id":["NS113233","R01 NS113233","S10 OD010662"],"pubmed_authors":["Rigo F","Centa JL","Rechtzigel MJ","Smit T","Jafar-Nejad P","Weimer JM","Hunyara JL","Leppert HG","Pfeifer WL","Swier VJ","Booth CD","Albert K","Duelli FJ","Stratton MP","Drack AV","Hastings ML"],"additional_accession":[]},"is_claimable":false,"name":"Therapeutic antisense oligonucleotide mitigates retinal dysfunction in a pig model of CLN3 Batten disease.","description":"CLN3 Batten disease is a lethal pediatric neurodegenerative disease caused by mutations in the CLN3 gene. Typically, the disease manifests as vision loss in early childhood and progresses to neurological dysfunction and death in young adulthood. Most therapeutic developments have focused on treating the brain and may not protect against vision loss, which greatly affects quality of life. We have previously shown that a splice-switching antisense oligonucleotide (ASO) delivered to the central nervous system can reduce neurological disease burden in mouse models of CLN3 disease. Here, we apply a similar ASO approach for treating retinal dysfunction in a pig model of CLN3 Batten disease, which is more representative of human vision. A single intravitreal injection of ASO induces robust exon s","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Oct","modification":"2026-06-05T13:04:07.097Z","creation":"2026-05-17T03:13:26.897Z"},"accession":"S-EPMC12585909","cross_references":{"pubmed":["41189054"],"doi":["10.1093/nar/gkaf1141"]}}